OOIR: Observatory of International Research

Papers

(The H4-Index of British Journal of Pharmacology is 48. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020	579
The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research	320
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors	316
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes	314
Current pharmacological treatments for COVID‐19: What's next?	193
A practical guide for transparent reporting of research on natural products in the British Journal of Pharmacology: Reproducibility of natural product research	177
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Introduction and Other Protein Targets	175
Planning experiments: Updated guidance on experimental design and analysis and their reporting III	170
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Ion channels	168
Update of P2X receptor properties and their pharmacology: IUPHAR Review 30	160
Animal models of mechanisms of SARS‐CoV‐2 infection and COVID‐19 pathology	149
Update of P2Y receptor pharmacology: IUPHAR Review 27	149
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Catalytic receptors	145
A hypothesis for pathobiology and treatment of COVID‐19: The centrality of ACE1/ACE2 imbalance	142
Arctigenin protects against depression by inhibiting microglial activation and neuroinflammation via HMGB1/TLR4/NF‐κB and TNF‐α/TNFR1/NF‐κB pathways	114
The role of mitochondrial dynamics in cardiovascular diseases	112
Quercetin induces p53‐independent cancer cell death through lysosome activation by the transcription factor EB and Reactive Oxygen Species‐dependent ferroptosis	112
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Transporters	108
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Nuclear hormone receptors	98
Statins: Could an old friend help in the fight against COVID‐19?	97
Berberine protects against diabetic kidney disease via promoting PGC‐1α‐regulated mitochondrial energy homeostasis	87
Community guidelines for GPCR ligand bias: IUPHAR review 32	84
Astaxanthin ameliorates oxidative stress and neuronal apoptosis via SIRT1/NRF2/Prx2/ASK1/p38 after traumatic brain injury in mice	77
Nuciferine protects against folic acid‐induced acute kidney injury by inhibiting ferroptosis	75
The potential of cannabidiol in the COVID‐19 pandemic	75

Non‐steroidal anti‐inflammatory drugs, prostaglandins, and COVID‐19	70
Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS‐CoV‐2 infection in vitro	69
Cyanidin‐3‐O‐glucoside improves non‐alcoholic fatty liver disease by promoting PINK1‐mediated mitophagy in mice	68
Zebrafish as a tractable model of human cardiovascular disease	68
Unfractionated heparin inhibits live wild type SARS‐CoV‐2 cell infectivity at therapeutically relevant concentrations	68
Astaxanthin attenuates hepatic damage and mitochondrial dysfunction in non‐alcoholic fatty liver disease by up‐regulating the FGF21/PGC‐1α pathway	67
Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease	64
Butyrate ameliorates skeletal muscle atrophy in diabetic nephropathy by enhancing gut barrier function and FFA2‐mediated PI3K/Akt/mTOR signals	64
Potential therapeutic targets and promising drugs for combating SARS‐CoV‐2	64
Anti‐inflammatory and antiviral roles of hydrogen sulfide: Rationale for considering H₂S donors in COVID‐19 therapy	60
Leonurine alleviates ferroptosis in cisplatin‐induced acute kidney injury by activating the Nrf2 signalling pathway	59
Sex‐related differences in COVID‐19 lethality	59
A rational roadmap for SARS‐CoV‐2/COVID‐19 pharmacotherapeutic research and development: IUPHAR Review 29	58
A rationale for targeting the P2X7 receptor in Coronavirus disease 19	56
Taxane‐induced neurotoxicity: Pathophysiology and therapeutic perspectives	56
Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders	55
Osteosarcoma mechanobiology and therapeutic targets	54
Clinical applications for exosomes: Are we there yet?	54
Eating microRNAs: pharmacological opportunities for cross‐kingdom regulation and implications in host gene and gut microbiota modulation	52
A systematic review of minor phytocannabinoids with promising neuroprotective potential	52
Mechanisms of enzalutamide resistance in castration‐resistant prostate cancer and therapeutic strategies to overcome it	51
Review of delta‐8‐tetrahydrocannabinol (Δ⁸‐THC): Comparative pharmacology with Δ⁹‐THC	50
Acinar cell NLRP3 inflammasome and gasdermin D (GSDMD) activation mediates pyroptosis and systemic inflammation in acute pancreatitis	49
Triptolide prevents LPS‐induced skeletal muscle atrophy via inhibiting NF‐κB/TNF‐α and regulating protein synthesis/degradation pathway	48
Omega‐3 polyunsaturated fatty acids and hypertension: a review of vasodilatory mechanisms of docosahexaenoic acid and eicosapentaenoic acid	48
Identification of endogenous 1‐aminopyrene as a novel mediator of progressive chronic kidney disease via aryl hydrocarbon receptor activation	48
Oxiapoptophagy: A type of cell death induced by some oxysterols	48